These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21124044)

  • 21. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
    Janjigian YY; Azzoli CG; Krug LM; Pereira LK; Rizvi NA; Pietanza MC; Kris MG; Ginsberg MS; Pao W; Miller VA; Riely GJ
    Clin Cancer Res; 2011 Apr; 17(8):2521-7. PubMed ID: 21248303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skin toxicities associated with epidermal growth factor receptor inhibitors.
    Li T; Perez-Soler R
    Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR pathway in advanced non-small cell lung cancer.
    Merlo V; Longo M; Novello S; Scagliotti GV
    Front Biosci (Schol Ed); 2011 Jan; 3(2):501-17. PubMed ID: 21196393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
    Goldberg SB; Oxnard GR; Digumarthy S; Muzikansky A; Jackman DM; Lennes IT; Sequist LV
    Oncologist; 2013; 18(11):1214-20. PubMed ID: 24072220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
    J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Subramanian J; Fernandes AW; Laliberté F; Pavilack M; DerSarkissian M; Duh MS
    Lung Cancer; 2019 Dec; 138():131-138. PubMed ID: 31733614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
    Blackledge G; Averbuch S
    Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
    Cortot AB
    Rev Pneumol Clin; 2010 Dec; 66(6):367-74. PubMed ID: 21167447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Lin CC; Yang CH
    Target Oncol; 2009 Jan; 4(1):37-44. PubMed ID: 19343300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
    Ma W; Xu M; Liu Y; Liu H; Huang J; Zhu Y; Ji LJ; Qi X
    Int J Cancer; 2015 Jul; 137(2):409-19. PubMed ID: 25471638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights in drug development for the non-small cell lung cancer therapy.
    Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
    Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
    Reck M; Kranich AL; Steinbach AK; Gatzemeier U
    Med Klin (Munich); 2005 Dec; 100(12):785-93. PubMed ID: 16453093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis.
    Chen P; Wang L; Liu B; Zhang HZ; Liu HC; Zou Z
    Eur J Clin Pharmacol; 2011 Mar; 67(3):235-43. PubMed ID: 21207017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
    Falchook GS; Naing A; Hong DS; Zinner R; Fu S; Piha-Paul SA; Tsimberidou AM; Morgan-Linnell SK; Jiang Y; Bastida C; Wheler JJ; Kurzrock R
    Oncotarget; 2013 Jan; 4(1):118-27. PubMed ID: 23435217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
    Cancer Discov; 2014 Nov; 4(11):OF18. PubMed ID: 25367959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
    Tanaka S; Sakamori Y; Niimi M; Hazama M; Kim YH; Yanagihara K
    Trials; 2011 May; 12():120. PubMed ID: 21569411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.
    Belani CP; Nemunaitis JJ; Chachoua A; Eisenberg PD; Raez LE; Cuevas JD; Mather CB; Benner RJ; Meech SJ
    Cancer Biol Ther; 2013 Jul; 14(7):557-63. PubMed ID: 23792641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.